Entyvio (vedolizumab) is a gut-selective monoclonal antibody approved for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in adults. It is typically prescribed for patients who have not responded adequately to conventional therapies such as corticosteroids, immunomodulators, or tumor necrosis factor (TNF) inhibitors.

Unlike many other biologics that affect the whole immune system, Entyvio is designed to specifically target α4β7 integrin, a protein involved in the movement of white blood cells into the gastrointestinal tract. By blocking this pathway, Entyvio helps reduce inflammation in the gut without broadly suppressing the immune system.

Entyvio is given by intravenous (IV) infusion at induction doses (weeks 0, 2, and 6) and then every 8 weeks for maintenance therapy. Clinical trials have shown that Entyvio can induce and maintain remission, reduce corticosteroid dependence, and improve quality of life in patients with inflammatory bowel disease (IBD).

Common side effects include headache, joint pain, nausea, fever, and infusion-related reactions. Serious risks, though rare, may include infections and hypersensitivity reactions. Because Entyvio acts selectively in the gut, it generally has a more favorable safety profile compared to systemic immunosuppressants.